LBCL Guidelines Webinar Series

As part of EHA’s commitment to supporting the professional growth of hematology professionals, we are hosting the first session of our Clinical Guidelines Webinar Series on ‘Large B‑cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‑up,’ published in the open‑access journal HemaSphere in December 2025.

This four‑part educational program has been developed by experts within EHA’s community for professionals involved in the care of patients with aggressive large B‑cell lymphomas.

This series is designed to support you in everyday clinical work, by helping you:

  • Interpret and apply EHA guideline recommendations across common and challenging LBCL scenarios
  • Compare your own decision-making with that of peers across Europe
  • Navigate areas where evidence exists, but practice varies
  • Make confident, guideline-aligned choices under real-world constraints

Each concise, 1-hour session focuses on a specific stage of the LBCL care pathway and combines expert input with open exchange among colleagues, reflecting how decisions are made in practice.

The faculty includes guideline authors and experienced EHA members from across Europe. Moderated by expert Chairs, the webinars create a shared space for peer learning, discussion, and reflection on current practice.

Webinar topics

Webinar 1: Treatment Strategies for Newly Diagnosed LBCL

March 12, 16:00 – 17:00 CET

Moderator: Wojciech Jurczak

Speakers: Christopher Fox, Sirpa Leppä & Maria Gomes da Silva

This webinar provides a clear and structured overview of current first‑line treatment strategies for LBCL, grounded in the latest guideline recommendations. Attendees will gain a deeper understanding of how to select appropriate frontline regimens and how to manage the unique considerations of elderly or frail individuals.

Sign up for Webinar 1

Webinar 2: Management of Relapsed/Refractory LBCL

March 20, 15:30 – 16:30 CET

Moderator: Igor Aurer

Speakers: Marek Trneny, Igor Aurer & Andrew Davies

Relapsed or refractory LBCL remains an area where clinical decisions have a significant impact on survival outcomes. This session unpacks the full landscape of second‑line and later‑line treatment pathways, with a focus on CAR‑T therapy, ASCT eligibility, and strategies for patients who cannot undergo intensive treatments.

Sign up for Webinar 2

Webinar 3: Supportive Care, Complications & Follow‑Up

March 24, 16:00 – 17:00 CET

Moderator: Timothy Illidge

Speakers: Umberto Vitolo & Hervé Tilly

This webinar focuses on the essential but often under‑discussed aspects of LBCL care: managing treatment‑related complications, providing appropriate supportive interventions, and designing long‑term follow‑up plans that account for late effects and survivorship needs.

Sign up for Webinar 3

Webinar 4: Diagnosis, Staging & Response Assessment

Early April (To be announced)

Moderator: Armando Lopez-Guillermo

Speakers: Anne-Segolène

Accurate diagnosis and staging are cornerstones of effective LBCL management. This webinar provides a streamlined overview of current pathology standards, the expanding role of immunohistochemistry and molecular techniques, and the central importance of PET‑based response evaluation.

Sign up for Webinar 4

Webinar sponsor

The technical production of this webinar series was supported by AbbVie.

Concept development, speaker selection, and content creation were carried out independently by EHA.

Share